Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

NCT05577312 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.

NCT NCT05577312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05577312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
Lead sponsor
Bioray Laboratories
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 2, 2022
Completion date
July 10, 2027
Enrollment
39 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia